Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.

Apoptosis : an international journal on programmed cell death - 1 Aug 2020

Zhong Boya, Shingyoji Masato, Hanazono Michiko, Nguyễn Thi Thanh, Morinaga Takao, Tada Yuji, Shimada Hideaki, Hiroshima Kenzo, Tagawa Masatoshi

Abstract excerpt

A majority of mesothelioma had the wild-type p53 genotype but was defective of p53 functions primarily due to a genetic defect in INK4A/ARF region. We examined a growth suppressive activity of CP-31398 which was developed to restore the p53 functions irrespective of the genotype in mesothelioma with wild-type or mutated p53. CP-31398 up-regulated p53 levels in cells with wild-type p53 genotype but induced cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Checkpoint Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Drug Synergism

Share to Focal Adhesion Kinase 1

Share to Imidazoles

Share to Proto-Oncogene Proteins c-mdm2

Share to Ubiquitination

Source

Identifiers

PMID: 32468177
DOI: 10.1007/s10495-020-01612-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.PMID 32468177Read ↗

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype.Semantic proximity Read ↗

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Semantic proximity Read ↗

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Semantic proximity Read ↗

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.Semantic proximity Read ↗

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.Semantic proximity Read ↗

CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.Semantic proximity Read ↗

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAKSemantic proximity Read ↗

Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway.Semantic proximity Read ↗

Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf–MAPK PathwaysSemantic proximity Read ↗

Nutlin-3a selects for cells harbouring TP53 mutations.Semantic proximity Read ↗

Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathwaySemantic proximity Read ↗

Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.